Ultragenyx Pharmaceutical (RARE) Common Equity (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Common Equity for 14 consecutive years, with -$236.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity fell 263.89% year-over-year to -$236.0 million; the TTM figure through Mar 2026 stood at -$236.0 million (down 263.89% YoY), while the FY2025 annual figure was -$80.0 million, down 131.37% from the prior year.
• Common Equity slipped to -$236.0 million in Q1 2026 per RARE's latest filing, from -$80.0 million in the prior quarter.
• Across five years, Common Equity topped out at $796.4 million in Q1 2022 and bottomed at -$236.0 million in Q1 2026.
• Historically, Common Equity has averaged $242.0 million across 5 years, with a median of $220.5 million in 2023.
• Annual changes were most pronounced in 2024 — Common Equity jumped 993.61% — and 2026, when it plunged 263.89%.
• Ultragenyx Pharmaceutical's Common Equity stood at $352.0 million in 2022, then slipped by 21.88% to $275.0 million in 2023, then declined by 7.27% to $255.0 million in 2024, then slumped by 131.37% to -$80.0 million in 2025, then tumbled by 195.0% to -$236.0 million in 2026.
• Business Quant data shows RARE's Common Equity at -$236.0 million in Q1 2026, -$80.0 million in Q4 2025, and $9.2 million in Q3 2025.